Targeted Therapy for Colon Cancer in India: Bevacizumab, Cetuximab & What Actually Determines Which You Need

Bevacizumab or cetuximab? The answer depends on your RAS status, BRAF status, and where your primary tumour sits. FIRE-3 showed 5-year survival nearly doubled with cetuximab in left-sided tumours. This guide explains the clinical decision logic — and what all of this costs in India.

By Gaf Healthcare Editorial Team

2026-05-14

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>Targeted Therapy for Colon Cancer in India: Bevacizumab, Cetuximab & More (2025) | GAF Healthcare</title> <meta name="description" content="Bevacizumab vs cetuximab for colon cancer — which is right for you depends on RAS mutation, tumour sidedness, and whether surgery is the goal. Everything explained, with India cost comparison."> <link rel="preconnect" href="https://fonts.googleapis.com"> <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin> <link href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=DM+Sans:wght@300;400;500;600&display=swap" rel="stylesheet"> <style> ,::before,*::after{box-sizing:border-box;margin:0;padding:0} :root{ --bg:#f5f2ec;--surface:#fff; --green-mid:#2d6e4e;--green-link:#2a6347; --green-light:#eaf4ef;--green-border:#b5d9c5; --green-cta:#1e5c3a;--green-hover:#174d2f; --red:#b83a2a;--amber:#c97d10;--orange-soft:#f4ede3; --blue-soft:#e8f2ff;--blue-border:#93c0e8;--blue-label:#185fa5; --purple-soft:#f0eeff;--purple-border:#b8a8e8;--purple-label:#4a3a9a; --text-primary:#1a1a18;--text-body:#2e2e2a; --text-muted:#6b6b62;--text-light:#8a8a80; --border:#ddd9d0;--border-light:#e8e4db;--stat-border:#d4cfc5; } html{scroll-behavior:smooth} body{font-family:'DM Sans',sans-serif;background:var(--bg);color:var(--text-body);font-size:17px;line-height:1.75;-webkit-font-smoothing:antialiased} .wrap{max-width:780px;margin:0 auto;padding:0 24px} .article-header{padding:52px 0 36px;border-bottom:1px solid var(--border);margin-bottom:40px} .breadcrumb{font-size:12px;color:var(--text-light);margin-bottom:20px;letter-spacing:.03em;text-transform:uppercase} .breadcrumb a{color:var(--green-link);text-decoration:none} .breadcrumb span{margin:0 6px;opacity:.5} h1{font-family:'Lora',Georgia,serif;font-size:clamp(28px,4vw,40px);font-weight:700;color:var(--text-primary);line-height:1.2;margin-bottom:18px;letter-spacing:-.01em} .meta{display:flex;align-items:center;gap:16px;flex-wrap:wrap;font-size:13px;color:var(--text-muted);margin-bottom:28px} .meta .sep{opacity:.4} .tag{background:var(--green-light);color:var(--green-mid);border:1px solid var(--green-border);border-radius:20px;padding:2px 12px;font-size:12px;font-weight:500} .lead{font-size:18px;line-height:1.8;color:var(--text-body);margin-bottom:22px} .body-text{font-size:17px;line-height:1.8;color:var(--text-body);margin-bottom:22px} h2{font-family:'Lora',Georgia,serif;font-size:clamp(22px,3vw,28px);font-weight:700;color:var(--text-primary);line-height:1.25;margin:52px 0 0;letter-spacing:-.01em} .rule{border:none;border-top:1px solid var(--border);margin:14px 0 24px} h3{font-family:'Lora',Georgia,serif;font-size:20px;font-weight:600;color:var(--text-primary);margin:32px 0 14px}

.toc{background:var(--surface);border:1px solid var(--border);border-radius:10px;padding:22px 26px 24px;margin:36px 0} .toc-hdr{display:flex;align-items:center;gap:8px;font-size:11px;font-weight:600;letter-spacing:.08em;text-transform:uppercase;color:var(--text-muted);margin-bottom:14px} .toc ol{list-style:none;padding:0} .toc ol li{padding:4px 0} .toc ol li a{color:var(--green-link);text-decoration:none;font-size:15px;line-height:1.5} .toc ol li a:hover{text-decoration:underline}

.qa{background:var(--green-light);border:1.5px solid var(--green-border);border-radius:10px;padding:20px 24px 22px;margin:24px 0 28px} .qa-lbl{display:flex;align-items:center;gap:6px;font-size:10.5px;font-weight:700;letter-spacing:.1em;text-transform:uppercase;color:var(--amber);margin-bottom:10px} .qa-q{font-weight:600;color:var(--text-primary);font-size:16px;margin-bottom:10px} .qa p{font-size:15.5px;line-height:1.75;color:var(--text-body)} .qa strong{color:var(--text-primary)}

.illus-wrap{margin:32px 0 8px;background:var(--surface);border:1px solid var(--border);border-radius:12px;overflow:hidden} .illus-wrap figure{margin:0} .illus-wrap svg{display:block;width:100%;height:auto} .illus-cap{padding:12px 18px;font-size:13px;color:var(--text-muted);border-top:1px solid var(--border-light);line-height:1.55;font-style:italic}

.stat-bar{display:grid;grid-template-columns:repeat(4,1fr);border:1px solid var(--stat-border);border-radius:8px;overflow:hidden;margin:22px 0 28px;background:var(--surface)} .sc{padding:16px 18px;border-right:1px solid var(--stat-border)} .sc:last-child{border-right:none} .sl{font-size:10px;font-weight:600;letter-spacing:.1em;text-transform:uppercase;color:var(--text-muted);margin-bottom:6px} .sv{font-family:'Lora',Georgia,serif;font-size:22px;font-weight:700;color:var(--green-mid);line-height:1.1} @media(max-width:600px){.stat-bar{grid-template-columns:repeat(2,1fr)}.sc:nth-child(2){border-right:none}.sc:nth-child(3){border-top:1px solid var(--stat-border)}.sc:nth-child(4){border-right:none;border-top:1px solid var(--stat-border)}}

/ Drug cards / .drug-card{background:var(--surface);border:1.5px solid var(--border);border-radius:10px;padding:22px 22px 18px;margin-bottom:20px} .drug-card.bev{border-left:4px solid var(--blue-label)} .drug-card.cet{border-left:4px solid #2d6e4e} .drug-card.enc{border-left:4px solid var(--purple-label)} .drug-card.her{border-left:4px solid var(--amber)} .drug-badge{font-size:11px;font-weight:700;letter-spacing:.08em;text-transform:uppercase;margin-bottom:6px;display:inline-block;border-radius:4px;padding:2px 8px} .bev .drug-badge{background:var(--blue-soft);color:var(--blue-label)} .cet .drug-badge{background:#eaf4ef;color:#2d6e4e} .enc .drug-badge{background:var(--purple-soft);color:var(--purple-label)} .her .drug-badge{background:#fff8e8;color:#8a6010} .drug-card h3{font-family:'Lora',Georgia,serif;font-size:19px;font-weight:700;color:var(--text-primary);margin:0 0 10px} .drug-meta{display:flex;gap:16px;flex-wrap:wrap;margin-bottom:12px} .dm{font-size:12.5px;color:var(--text-muted)} .dm strong{color:var(--text-primary)}

/ Decision tree / .decision-tree{background:var(--surface);border:1px solid var(--border);border-radius:12px;overflow:hidden;margin:24px 0 28px} .dt-header{background:var(--green-cta);padding:14px 20px;font-size:12px;font-weight:700;color:#fff;letter-spacing:.05em;text-transform:uppercase} .dt-row{display:flex;align-items:flex-start;gap:16px;padding:16px 20px;border-bottom:1px solid var(--border-light)} .dt-row:last-child{border-bottom:none} .dt-condition{min-width:200px;font-size:14px;font-weight:600;color:var(--text-primary);padding-right:16px} .dt-result{font-size:14.5px;color:var(--text-body);line-height:1.6} .dt-result strong{color:var(--text-primary)} @media(max-width:540px){.dt-row{flex-direction:column;gap:6px}.dt-condition{min-width:auto}}

/ Big table / .big-table{width:100%;border-collapse:collapse;border:1px solid var(--border);border-radius:10px;overflow:hidden;font-size:14.5px;margin:20px 0 28px;background:var(--surface)} .big-table th{background:var(--green-cta);color:#fff;font-weight:600;font-size:12px;letter-spacing:.05em;text-transform:uppercase;padding:13px 16px;text-align:left} .big-table td{padding:13px 16px;border-top:1px solid var(--border-light);vertical-align:top;line-height:1.6} .big-table tr:nth-child(even) td{background:#faf9f6} .big-table td.hi{color:var(--green-mid);font-weight:600} .big-table td.key{font-weight:600;color:var(--text-primary)}

/ Callouts / .callout-red{border-left:3px solid var(--red);padding:14px 20px;margin:28px 0} .callout-red-lbl{font-size:10.5px;font-weight:700;letter-spacing:.1em;text-transform:uppercase;color:var(--red);margin-bottom:8px} .callout-red p{font-size:15.5px;line-height:1.75;color:var(--text-body)} .callout-red strong{color:var(--text-primary)} .callout-amber{border-left:3px solid var(--amber);padding:14px 20px;margin:28px 0;background:var(--orange-soft)} .callout-amber-lbl{font-size:10.5px;font-weight:700;letter-spacing:.1em;text-transform:uppercase;color:var(--amber);margin-bottom:8px} .callout-amber p{font-size:15.5px;line-height:1.75;color:var(--text-body)} .callout-amber strong{color:var(--text-primary)} .callout-blue{border-left:3px solid var(--blue-label);padding:14px 20px;margin:28px 0;background:var(--blue-soft)} .callout-blue-lbl{font-size:10.5px;font-weight:700;letter-spacing:.1em;text-transform:uppercase;color:var(--blue-label);margin-bottom:8px} .callout-blue p{font-size:15.5px;line-height:1.75;color:var(--text-body)} .callout-blue strong{color:var(--text-primary)} .callout-green{border-left:3px solid var(--green-mid);padding:14px 20px;margin:28px 0;background:var(--green-light)} .callout-green-lbl{font-size:10.5px;font-weight:700;letter-spacing:.1em;text-transform:uppercase;color:var(--green-mid);margin-bottom:8px} .callout-green p{font-size:15.5px;line-height:1.75;color:var(--text-body)} .callout-green strong{color:var(--text-primary)}

blockquote{border-left:3px solid var(--green-mid);padding:14px 20px;margin:28px 0} blockquote p{font-family:'Lora',Georgia,serif;font-size:18px;font-style:italic;line-height:1.7;color:var(--text-primary)}

.link-box{border:1px solid var(--green-border);border-radius:8px;padding:14px 18px;margin:24px 0;background:var(--surface)} .link-box a{color:var(--green-link);text-decoration:none;font-weight:600;font-size:15px;display:block;margin-bottom:4px} .link-box a::before{content:'→ '} .link-box a:hover{text-decoration:underline} .link-box p{font-size:13.5px;color:var(--text-muted);line-height:1.5;margin:0}

.cta-dark{background:var(--green-cta);border-radius:12px;padding:26px 28px 28px;margin:32px 0} .cta-dark h3{font-family:'DM Sans',sans-serif;font-size:17px;font-weight:600;color:#fff;margin:0 0 8px} .cta-dark p{font-size:14.5px;color:rgba(255,255,255,.75);margin-bottom:18px;line-height:1.6} .btns{display:flex;gap:12px;flex-wrap:wrap} .btn-w{display:inline-block;background:#fff;color:var(--green-cta);font-size:14px;font-weight:600;padding:11px 22px;border-radius:6px;text-decoration:none} .btn-w:hover{background:#f0f0f0} .btn-gh{display:inline-block;background:rgba(255,255,255,.15);border:1.5px solid rgba(255,255,255,.8);color:#fff;font-size:14px;font-weight:600;padding:11px 22px;border-radius:6px;text-decoration:none} .btn-gh:hover{background:rgba(255,255,255,.25)} .cta-light{border:1px solid var(--green-border);border-radius:10px;padding:22px 24px 24px;margin:28px 0;background:var(--surface)} .cta-light h3{font-family:'DM Sans',sans-serif;font-size:16px;font-weight:600;color:var(--text-primary);margin:0 0 7px} .cta-light p{font-size:14px;color:var(--text-muted);margin-bottom:16px;line-height:1.6} .btn-g{display:inline-block;background:var(--green-cta);color:#fff;font-size:14px;font-weight:600;padding:11px 22px;border-radius:6px;text-decoration:none} .btn-g:hover{background:var(--green-hover)}

.sources{font-size:12.5px;color:var(--text-light);margin:8px 0 32px;font-style:italic} .faq-item{border-bottom:1px solid var(--border-light);padding:18px 0} .faq-item:last-child{border-bottom:none} .faq-q{font-weight:600;color:var(--text-primary);font-size:16px;margin-bottom:8px} .faq-a{font-size:15px;color:var(--text-body);line-height:1.75} .final-cta{background:var(--green-cta);border-radius:14px;padding:38px 36px 40px;margin:48px 0 24px;text-align:center} .final-cta h2{font-family:'Lora',Georgia,serif;font-size:26px;color:#fff;margin:0 0 12px} .final-cta p{color:rgba(255,255,255,.8);font-size:15.5px;max-width:520px;margin:0 auto 24px;line-height:1.7} .final-cta .btns{justify-content:center} a{color:var(--green-link)} strong{color:var(--text-primary)} @media(max-width:640px){.final-cta{padding:28px 22px 30px}.btns{flex-direction:column;align-items:flex-start}.final-cta .btns{align-items:center}} </style> </head> <body> <div class="wrap">

<header class="article-header"> <div class="breadcrumb"> <a href="https://gafhealthcare.in">GAF Healthcare</a><span>›</span> <a href="https://gafhealthcare.in/resources/blog">Blog</a><span>›</span> Targeted Therapy Colon Cancer India </div>

<h1>Targeted Therapy for Colon Cancer in India: Bevacizumab, Cetuximab & What Actually Determines Which You Need</h1>

<div class="meta"> <span>Updated May 2025</span><span class="sep">·</span> <span>12 min read</span><span class="sep">·</span> <span class="tag">Cluster 2 — Treatment Depth</span> <span class="tag">Precision Medicine</span> </div>

<p class="lead"> If you have Stage IV colon cancer and your oncologist is recommending a "targeted therapy" alongside chemotherapy, two questions matter immediately: which one, and why that one rather than the other? </p>

<p class="body-text"> The answer is not arbitrary. It depends on your RAS mutation status, your BRAF mutation status, where in the colon your primary tumour sits, and — critically — whether the goal of treatment is to shrink the cancer enough to make surgery possible, or to control it systemically for as long as possible. These are different goals, and they point to different drugs. </p>

<p class="body-text"> Most articles on this topic give you a definition of bevacizumab, a definition of cetuximab, and a price table. What they do not give you is the clinical logic that connects the biomarkers in your pathology report to the drug your oncologist should be recommending. This guide does that. </p>

<nav class="toc" aria-label="Table of contents"> <div class="toc-hdr"> <svg width="14" height="14" viewBox="0 0 16 16" fill="none"><rect x="1" y="2" width="14" height="2" rx="1" fill="currentColor"/><rect x="1" y="7" width="10" height="2" rx="1" fill="currentColor"/><rect x="1" y="12" width="12" height="2" rx="1" fill="currentColor"/></svg> What's in this guide </div> <ol> <li><a href="#what-is-targeted">What targeted therapy actually means in colon cancer</a></li> <li><a href="#biomarkers">The biomarker panel you need before any targeted therapy decision</a></li> <li><a href="#bevacizumab">Bevacizumab — how it works and when it wins</a></li> <li><a href="#cetuximab">Cetuximab and panitumumab — why left-sided tumours respond differently</a></li> <li><a href="#the-decision">The decision tree: which drug for which patient</a></li> <li><a href="#braf">BRAF V600E — the subgroup that needs a completely different approach</a></li> <li><a href="#her2">HER2 and NTRK — the rare but actionable targets</a></li> <li><a href="#side-effects">Side effects: what actually differs between the drugs</a></li> <li><a href="#india">Targeted therapy in India — cost, access, and quality</a></li> <li><a href="#faq">Frequently asked questions</a></li> </ol> </nav> </header>

<section id="what-is-targeted"> <h2>What targeted therapy actually means in colon cancer</h2> <hr class="rule">

<p class="body-text"> The phrase "targeted therapy" sounds more specific than it often is in practice. When oncologists use it for colon cancer, they generally mean one of two categories: drugs that block blood vessel growth (anti-angiogenic agents), or drugs that block signals on the surface of cancer cells (anti-EGFR agents). The distinction matters because the biology is completely different — and so is the patient selection. </p>

<p class="body-text"> Anti-angiogenic drugs — bevacizumab, ramucirumab, ziv-aflibercept — target a protein called VEGF (Vascular Endothelial Growth Factor). Tumours recruit new blood vessels to feed themselves; blocking VEGF starves them of this supply line. Anti-EGFR drugs — cetuximab, panitumumab — target a receptor on the surface of cancer cells called the Epidermal Growth Factor Receptor. When activated, EGFR signals the cell to grow and divide; blocking it cuts off that signal. </p>

<div class="illus-wrap"> <figure> <svg viewBox="0 0 740 270" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Two-panel mechanism diagram comparing how bevacizumab and cetuximab work against colon cancer. Left panel labelled Bevacizumab shows a cancer cell surrounded by blood vessels, with VEGF protein molecules shown as small orange circles being released from the tumour surface and binding to VEGF receptors on nearby blood vessel cells to stimulate new vessel growth. Bevacizumab antibody molecules shown in blue are intercepting and neutralising the VEGF molecules before they reach the blood vessel receptor, preventing angiogenesis. The outcome label reads Anti-angiogenic — starves tumour of blood supply — works regardless of RAS status. Right panel labelled Cetuximab shows a cancer cell with EGFR receptors on its surface shown as Y-shaped proteins. When activated by growth factor ligands shown as small green circles, the EGFR receptor sends a growth signal into the cell through the RAS signalling pathway shown as a chain of arrows inside the cell. Cetuximab antibody molecules are binding to and blocking the EGFR receptor, preventing ligand binding and stopping the growth signal. A red cross-out symbol is shown over the RAS pathway arrow indicating the signal is blocked. A callout notes that if the RAS gene is mutated the pathway fires autonomously regardless of EGFR blockade making cetuximab ineffective in RAS-mutated tumours."> <title>How bevacizumab and cetuximab work — anti-angiogenic versus anti-EGFR mechanisms in colon cancer</title> <desc>Side-by-side mechanism diagrams. Left shows bevacizumab capturing VEGF before it reaches blood vessels, cutting off tumour blood supply regardless of RAS status. Right shows cetuximab blocking EGFR receptor but only working when RAS is wild-type — mutated RAS bypasses the blockade.</desc>

<text x="185" y="32" font-family="DM Sans,sans-serif" font-size="13" font-weight="700" fill="#185fa5" text-anchor="middle">BEVACIZUMAB — Anti-angiogenic</text> <text x="185" y="46" font-family="DM Sans,sans-serif" font-size="10" fill="#8a8a80" text-anchor="middle">Blocks VEGF · Works regardless of RAS status</text>

<ellipse cx="130" cy="150" rx="52" ry="46" fill="#fdf0ee" stroke="#d9857a" stroke-width="1.5"/> <text x="130" y="148" font-family="DM Sans,sans-serif" font-size="9.5" fill="#b83a2a" text-anchor="middle" font-weight="600">Tumour</text> <text x="130" y="161" font-family="DM Sans,sans-serif" font-size="9" fill="#8a4030" text-anchor="middle">releases VEGF</text>

<circle cx="192" cy="112" r="7" fill="#c97d10" opacity=".85"/> <text x="192" y="116" font-family="DM Sans,sans-serif" font-size="7" fill="#fff" text-anchor="middle" font-weight="700">V</text> <circle cx="200" cy="142" r="7" fill="#c97d10" opacity=".85"/> <text x="200" y="146" font-family="DM Sans,sans-serif" font-size="7" fill="#fff" text-anchor="middle" font-weight="700">V</text> <circle cx="195" cy="172" r="7" fill="#c97d10" opacity=".85"/> <text x="195" y="176" font-family="DM Sans,sans-serif" font-size="7" fill="#fff" text-anchor="middle" font-weight="700">V</text>

<path d="M228 108 C240 104 252 108 255 118 C258 128 250 136 238 136 C226 136 220 128 224 118 Z" fill="#185fa5" opacity=".2" stroke="#185fa5" stroke-width="1.5"/> <text x="240" y="122" font-family="DM Sans,sans-serif" font-size="8" fill="#185fa5" text-anchor="middle" font-weight="600">Bev</text> <text x="255" y="110" font-family="DM Sans,sans-serif" font-size="8" fill="#185fa5">✕ blocks</text>

<rect x="285" y="100" width="60" height="100" rx="30" fill="#f0d8d0" stroke="#c8a0a0" stroke-width="1.5" opacity=".6"/> <text x="315" y="148" font-family="DM Sans,sans-serif" font-size="9" fill="#8a4040" text-anchor="middle">Blood</text> <text x="315" y="161" font-family="DM Sans,sans-serif" font-size="9" fill="#8a4040" text-anchor="middle">vessel</text> <text x="315" y="174" font-family="DM Sans,sans-serif" font-size="9" fill="#8a4040" text-anchor="middle">blocked</text>

<text x="185" y="222" font-family="DM Sans,sans-serif" font-size="10.5" fill="#185fa5" text-anchor="middle" font-weight="700">Tumour starved of blood supply</text> <text x="185" y="237" font-family="DM Sans,sans-serif" font-size="9.5" fill="#5a5a50" text-anchor="middle">RAS status irrelevant — all patients can receive</text>

<text x="555" y="32" font-family="DM Sans,sans-serif" font-size="13" font-weight="700" fill="#2d6e4e" text-anchor="middle">CETUXIMAB — Anti-EGFR</text> <text x="555" y="46" font-family="DM Sans,sans-serif" font-size="10" fill="#8a8a80" text-anchor="middle">Blocks EGFR · Only works if RAS is wild-type</text>

<ellipse cx="490" cy="150" rx="52" ry="46" fill="#fdf0ee" stroke="#d9857a" stroke-width="1.5"/> <text x="490" y="145" font-family="DM Sans,sans-serif" font-size="9.5" fill="#b83a2a" text-anchor="middle" font-weight="600">Cancer</text> <text x="490" y="158" font-family="DM Sans,sans-serif" font-size="9" fill="#8a4030" text-anchor="middle">cell</text>

<path d="M542 128 C548 124 556 124 560 130 C564 136 560 144 554 146 C548 148 542 144 540 138 Z" fill="#2d6e4e" opacity=".3" stroke="#2d6e4e" stroke-width="1.5"/> <text x="550" y="138" font-family="DM Sans,sans-serif" font-size="7.5" fill="#2d6e4e" text-anchor="middle" font-weight="700">EGFR</text>

<ellipse cx="590" cy="128" rx="20" ry="14" fill="#eaf4ef" stroke="#2d6e4e" stroke-width="1.5"/> <text x="590" y="132" font-family="DM Sans,sans-serif" font-size="8" fill="#2d6e4e" text-anchor="middle" font-weight="600">Cet</text> <line x1="570" y1="130" x2="562" y2="133" stroke="#2d6e4e" stroke-width="1.5" marker-end="url(#a2)"/>

<path d="M540 148 L510 158 L510 175" fill="none" stroke="#b83a2a" stroke-width="1.5" stroke-dasharray="3,2"/> <text x="500" y="188" font-family="DM Sans,sans-serif" font-size="8.5" fill="#b83a2a" text-anchor="middle">RAS pathway</text> <text x="500" y="199" font-family="DM Sans,sans-serif" font-size="8.5" fill="#b83a2a" text-anchor="middle">✕ BLOCKED</text>

<rect x="605" y="155" width="110" height="52" rx="6" fill="#fdf0ee" stroke="#d9857a" stroke-width="1"/> <text x="660" y="170" font-family="DM Sans,sans-serif" font-size="9" fill="#b83a2a" text-anchor="middle" font-weight="600">If RAS MUTATED:</text> <text x="660" y="183" font-family="DM Sans,sans-serif" font-size="8.5" fill="#8a4030" text-anchor="middle">pathway fires on its</text> <text x="660" y="195" font-family="DM Sans,sans-serif" font-size="8.5" fill="#8a4030" text-anchor="middle">own — cetuximab fails</text>

<text x="555" y="222" font-family="DM Sans,sans-serif" font-size="10.5" fill="#2d6e4e" text-anchor="middle" font-weight="700">Growth signal blocked (if RAS wild-type)</text> <text x="555" y="237" font-family="DM Sans,sans-serif" font-size="9.5" fill="#5a5a50" text-anchor="middle">Only 50–55% of patients qualify — RAS testing mandatory</text>

<text x="370" y="258" font-family="DM Sans,sans-serif" font-size="9" fill="#8a8a80" text-anchor="middle" font-style="italic">© GAF Healthcare 2025 · Full biomarker panel — RAS, BRAF, HER2 — required before selecting targeted therapy</text> </svg> <figcaption class="illus-cap"> <strong>How bevacizumab and cetuximab work differently.</strong> Bevacizumab intercepts VEGF — the protein tumours use to recruit blood vessels — before it reaches its target. It works regardless of RAS status, making it available to all Stage IV patients. Cetuximab blocks the EGFR receptor that drives cancer cell growth — but only when the downstream RAS pathway is normal (wild-type). If RAS is mutated, the pathway fires independently even with the EGFR receptor blocked, rendering cetuximab ineffective and potentially harmful. </figcaption> </figure> </div>

<p class="body-text"> The critical difference in practice: bevacizumab can be given to any Stage IV colon cancer patient, regardless of their molecular profile. Cetuximab and panitumumab can only be given to patients whose tumours are RAS wild-type — and even within that group, the benefit depends heavily on where in the colon the primary tumour is located. </p>

<p class="sources">Sources: NCCN Colon Cancer v1.2025 · ESMO mCRC Guidelines 2023 · PMC Molecular Targets for mCRC Treatment 2020</p> </section>

<section id="biomarkers"> <h2>The biomarker panel you need before any targeted therapy decision</h2> <hr class="rule">

<div class="qa"> <div class="qa-lbl"><svg width="12" height="12" viewBox="0 0 16 16" fill="none"><path d="M8 1L10.09 5.26L15 6L11.5 9.4L12.18 14.28L8 12.08L3.82 14.28L4.5 9.4L1 6L5.91 5.26L8 1Z" fill="#c97d10"/></svg>Quick answer</div> <div class="qa-q">What tests do I need before starting targeted therapy for colon cancer?</div> <p>Before any targeted therapy decision for Stage III–IV colon cancer, you need: <strong>extended RAS testing</strong> (KRAS and NRAS exons 2, 3, and 4 — not just KRAS exon 2 alone), <strong>BRAF V600E mutation testing</strong>, <strong>MSI/MMR testing</strong>, and <strong>HER2 amplification testing</strong>. Together, these four tests define which treatment pathway you belong to. In India, this full panel costs $180–$320 at a CAP-accredited lab, with results in 7–14 days. In the US, the same panel costs $1,500–$3,500.</p> </div>

<p class="body-text"> A common and consequential error: some oncologists still test only KRAS exon 2 rather than running extended RAS testing. KRAS exon 2 detects approximately 40% of RAS mutations. Extended testing — covering KRAS and NRAS exons 2, 3, and 4 — detects another 10–15% of mutations that exon 2 alone misses. </p>

<p class="body-text"> A patient who tests wild-type on KRAS exon 2 alone but has a KRAS exon 3 or NRAS mutation would incorrectly be classified as eligible for cetuximab. Giving them cetuximab produces no benefit and may reduce survival. This is not a rare edge case — it happens, and it is entirely preventable with a test that costs $120–$200 in India. </p>

<div class="callout-red"> <div class="callout-red-lbl">Extended RAS testing — not KRAS exon 2 alone</div> <p>If your pathology report says only "KRAS wild-type" without specifying which exons were tested, the testing may be incomplete. <strong>You need KRAS exons 2, 3, and 4 AND NRAS exons 2, 3, and 4 — all tested, all reported.</strong> This is called extended RAS or all-RAS testing. NCCN and ESMO guidelines both specify this as mandatory before any anti-EGFR therapy. If you have not had extended RAS testing, request it before any cetuximab or panitumumab is given.</p> </div>

<div class="cta-light"> <h3>Need extended RAS testing before your treatment starts?</h3> <p>GAF Healthcare arranges complete biomarker panels — extended RAS/BRAF, MSI/MMR, and HER2 — at CAP-accredited Indian labs. Bring your biopsy block or request it from your pathologist. Results in 7–14 days.</p> <a href="https://gafhealthcare.in/treatments/colon-cancer-treatment" class="btn-g">Arrange Biomarker Testing →</a> </div>

<p class="sources">Sources: NCCN Colon Cancer v1.2025 · ESMO Biomarker Guidelines for mCRC 2023 · FDA Approval Summary Cetuximab — extended RAS requirement</p> </section>

<section id="bevacizumab"> <h2>Bevacizumab — how it works and when it wins</h2> <hr class="rule">

<div class="drug-card bev"> <span class="drug-badge">Bevacizumab (Avastin)</span> <h3>Anti-VEGF therapy — the universal option</h3> <div class="drug-meta"> <div class="dm"><strong>Mechanism:</strong> Blocks VEGF-A, preventing tumour blood vessel formation</div> <div class="dm"><strong>Given with:</strong> FOLFOX, FOLFIRI, or CAPOX</div> <div class="dm"><strong>Eligible patients:</strong> Any RAS/BRAF status</div> <div class="dm"><strong>India cost:</strong> $600–$900 per cycle</div> </div>

<p class="body-text"> Bevacizumab is the simpler decision in terms of eligibility — if your tumour is RAS-mutated (approximately 45–50% of Stage IV patients), bevacizumab plus chemotherapy is your first-line targeted option, full stop. There is no alternative anti-EGFR pathway available to you. Even if your tumour is RAS wild-type, bevacizumab is a clinically valid choice in specific scenarios — particularly for right-sided tumours and patients where the treatment goal is disease control rather than maximal tumour shrinkage. </p>

<p class="body-text"> Adding bevacizumab to FOLFOX improves overall survival in metastatic colorectal cancer by approximately 4–5 months compared to FOLFOX alone. That is not a dramatic number in isolation. The real value of bevacizumab is its broad applicability — it works across molecular subtypes, it has a manageable side effect profile, and it can be continued across multiple lines of therapy (bevacizumab "beyond progression" is a validated strategy when switching chemotherapy backbones at disease progression). </p> </div>

<h3>When bevacizumab is the better choice over cetuximab</h3>

<p class="body-text"> Three scenarios where bevacizumab is the right first-line targeted agent even in RAS wild-type patients. </p>

<p class="body-text"> <strong>Right-sided primary tumours.</strong> FIRE-3 and CALGB 80405 both showed that cetuximab's survival advantage over bevacizumab disappears — or reverses — in patients with right-sided primary tumours (caecum through transverse colon). The biology of right-sided colon cancer is fundamentally different: higher rates of BRAF V600E mutation, more MSI-H disease, more mucinous histology. Bevacizumab performs more consistently across right and left-sided tumours; cetuximab's advantage is essentially confined to left-sided primaries. </p>

<p class="body-text"> <strong>When disease control, not shrinkage, is the goal.</strong> Bevacizumab produces more durable disease stabilisation with a lower risk of dramatic early progression. In older or frailer patients where maintaining quality of life over a longer period matters more than achieving a maximum response rate, this profile is genuinely preferable. </p>

<p class="body-text"> <strong>When skin toxicity is a concern.</strong> Cetuximab causes an acneiform rash in most patients — sometimes severe enough to affect quality of life significantly. For patients who are professionally visible or psychologically affected by skin changes, bevacizumab's different toxicity profile is a legitimate consideration. </p>

<p class="sources">Sources: AVF2107 Trial — Hurwitz et al. NEJM 2004 · FIRE-3 Final Analysis, BJC 2021 · NCCN Colon Cancer v1.2025</p> </section>

<section id="cetuximab"> <h2>Cetuximab and panitumumab — why left-sided tumours respond differently</h2> <hr class="rule">

<div class="drug-card cet"> <span class="drug-badge">Cetuximab (Erbitux) / Panitumumab (Vectibix)</span> <h3>Anti-EGFR therapy — powerful in the right patients</h3> <div class="drug-meta"> <div class="dm"><strong>Mechanism:</strong> Blocks EGFR receptor, preventing downstream growth signalling</div> <div class="dm"><strong>Eligible patients:</strong> RAS wild-type only (all-RAS extended testing required)</div> <div class="dm"><strong>Best response:</strong> Left-sided primary tumours, RAS/BRAF wild-type</div> <div class="dm"><strong>India cost:</strong> Cetuximab $700–$1,100/cycle; Panitumumab $800–$1,300/cycle</div> </div>

<p class="body-text"> In the right patient — RAS wild-type, BRAF wild-type, left-sided primary — cetuximab is not merely equivalent to bevacizumab. It is substantially better. The FIRE-3 trial, which compared FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab in RAS wild-type metastatic colorectal cancer, found that 5-year survival rates were almost doubled for left-sided tumours treated with cetuximab: <strong>21% versus 11%</strong> with bevacizumab. Median OS was 33 months with cetuximab versus 26 months with bevacizumab in the per-protocol population. </p>

<p class="body-text"> The mechanism for why left-sided tumours respond better is not fully elucidated, but tumour sidedness correlates with deep molecular differences in EGFR pathway dependence, tumour microenvironment composition, and response to EGFR inhibition. Right-sided tumours more frequently have co-occurring mutations that bypass EGFR signalling even when the receptor is blocked. </p> </div>

<div class="callout-green"> <div class="callout-green-lbl">The conversion strategy — when cetuximab becomes a surgical tool</div> <p>One of the most powerful use cases for cetuximab in metastatic colon cancer is <strong>conversion therapy</strong> — using the higher response rate of cetuximab-based regimens to shrink initially unresectable liver or lung metastases until they become surgically removable. Cetuximab plus FOLFOX or FOLFIRI achieves objective response rates of 60–70% in RAS wild-type, left-sided patients — significantly higher than bevacizumab combinations. For a patient where surgical resection of liver metastases would be potentially curative, achieving the best possible tumour response before surgery is the priority. <strong>In this scenario, for a left-sided RAS wild-type patient, cetuximab is almost always the correct choice.</strong></p> </div>

<h3>Panitumumab — the fully human alternative</h3>

<p class="body-text"> Panitumumab is a fully human anti-EGFR antibody, compared to cetuximab which is chimeric (part human, part mouse). In clinical practice, their efficacy is equivalent for the same patient population. The main difference is infusion-related: cetuximab carries a 3–5% risk of infusion hypersensitivity reactions, which are rare with panitumumab. The PARADIGM trial (2023) demonstrated panitumumab's superiority over bevacizumab in left-sided RAS wild-type metastatic CRC, confirming what FIRE-3 had established for cetuximab. </p>

<p class="sources">Sources: FIRE-3 Final Analysis BJC 2021 · PARADIGM Trial JAMA 2023 · CALGB 80405 — Venook et al. · NCCN Colon Cancer v1.2025</p> </section>

<section id="the-decision"> <h2>The decision tree: which drug for which patient</h2> <hr class="rule">

<p class="body-text"> This is the clinical logic your oncologist should be working through — and that you should be able to follow and interrogate. The decision is not complicated once the biomarker results are in hand. </p>

<div class="decision-tree"> <div class="dt-header">Targeted therapy decision guide — Stage IV colon cancer (RAS/BRAF results required)</div> <div class="dt-row"> <div class="dt-condition">RAS mutated (KRAS or NRAS)</div> <div class="dt-result"><strong>Bevacizumab + chemotherapy backbone</strong> (FOLFOX or FOLFIRI or CAPOX). Anti-EGFR therapy is contraindicated — do not receive cetuximab or panitumumab. India cost: $600–$900/cycle for bevacizumab.</div> </div> <div class="dt-row"> <div class="dt-condition">RAS wild-type + BRAF wild-type + Left-sided tumour</div> <div class="dt-result"><strong>Cetuximab or panitumumab + FOLFOX or FOLFIRI</strong> — this combination delivers the best response rates and survival in metastatic CRC. Particularly powerful if conversion to surgical resectability is the goal. India cost: $700–$1,100/cycle cetuximab.</div> </div> <div class="dt-row"> <div class="dt-condition">RAS wild-type + BRAF wild-type + Right-sided tumour</div> <div class="dt-result"><strong>Bevacizumab + chemotherapy</strong> is generally preferred — cetuximab's advantage over bevacizumab is largely absent in right-sided tumours. Some experts still offer cetuximab in right-sided disease for select patients, but bevacizumab is more consistent.</div> </div> <div class="dt-row"> <div class="dt-condition">BRAF V600E mutated</div> <div class="dt-result"><strong>Encorafenib + cetuximab</strong> (BEACON-CRC protocol) — do not use bevacizumab or standard anti-EGFR alone. See Section 6. India cost: $2,800–$4,200/cycle combination.</div> </div> <div class="dt-row"> <div class="dt-condition">MSI-H / dMMR</div> <div class="dt-result"><strong>Pembrolizumab first-line</strong> — see immunotherapy guide. Targeted therapy is secondary to immunotherapy for this molecular subgroup.</div> </div> <div class="dt-row"> <div class="dt-condition">HER2-amplified (3–5% of cases)</div> <div class="dt-result"><strong>Trastuzumab + pertuzumab or lapatinib</strong> — standard anti-EGFR therapy is less effective in HER2-amplified RAS wild-type disease. See Section 7. India cost: $1,200–$2,000/cycle.</div> </div> </div>

<blockquote> <p>"The question is never just 'bevacizumab or cetuximab.' It is: what is your RAS status, what is your BRAF status, where is your primary tumour, and what are we trying to achieve? Those four answers produce a specific recommendation. If your oncologist cannot articulate all four, push for a second opinion."</p> </blockquote>

<div class="cta-dark"> <h3>Have your RAS/BRAF results and not sure what they mean for your treatment?</h3> <p>Share your pathology report and biomarker panel with GAF Healthcare. Our oncology team will interpret the results and provide a specific targeted therapy recommendation — within 48 hours, free of charge.</p> <div class="btns"> <a href="https://gafhealthcare.in/treatments/colon-cancer-treatment" class="btn-w">Get Free Treatment Recommendation →</a> <a href="https://gafhealthcare.in/resources/blog/colon-cancer-treatment-india-international-patients" class="btn-gh">Full Patient Guide →</a> </div> </div>

<p class="sources">Sources: NCCN Colon Cancer v1.2025 · ESMO mCRC Guidelines 2023 · FIRE-3 BJC 2021 · FIRE-3 Refinement Study EJC 2025</p> </section>

<section id="braf"> <h2>BRAF V600E — the subgroup that needs a completely different approach</h2> <hr class="rule">

<p class="body-text"> BRAF V600E mutations occur in approximately 8–10% of Stage IV colon cancer patients. They are disproportionately associated with right-sided primaries, older patients, female sex, and MSI-H tumours. The prognosis is historically poor — BRAF-mutated metastatic colon cancer has median OS of approximately 12–14 months on standard chemotherapy, compared to 25–30 months in BRAF wild-type disease. </p>

<div class="drug-card enc"> <span class="drug-badge">Encorafenib + Cetuximab (BEACON-CRC)</span> <h3>Targeted combination for BRAF V600E mutated metastatic CRC</h3> <div class="drug-meta"> <div class="dm"><strong>Mechanism:</strong> Encorafenib inhibits mutated BRAF V600E; cetuximab blocks EGFR reactivation</div> <div class="dm"><strong>Line:</strong> Second-line after prior fluoropyrimidine-based therapy</div> <div class="dm"><strong>India cost:</strong> $2,800–$4,200 per cycle</div> </div>

<p class="body-text"> The BEACON-CRC trial established encorafenib plus cetuximab as the standard second-line treatment for BRAF V600E-mutated metastatic colorectal cancer. The combination produced median OS of 9.3 months — more than double the 5.9 months achieved with standard chemotherapy. Response rate was 26% versus 2%. </p>

<p class="body-text"> Why does this combination work when monotherapy does not? BRAF inhibition alone (as with vemurafenib or dabrafenib) is largely ineffective in colorectal cancer because blocking the mutant BRAF protein triggers a feedback reactivation of EGFR signalling. Adding cetuximab blocks this escape route, allowing the BRAF inhibitor to maintain its effect. This combination-required approach is fundamentally different from how BRAF inhibition works in melanoma, and it explains why BRAF-targeting in colorectal cancer required this specific dual strategy. </p> </div>

<div class="callout-amber"> <div class="callout-amber-lbl">BRAF V600E and first-line treatment</div> <p>In first-line therapy, BRAF V600E patients are typically treated with intensive chemotherapy — either FOLFOXIRI (three-drug chemotherapy) plus bevacizumab, or FOLFOX plus bevacizumab. Encorafenib plus cetuximab is currently approved for second-line use after prior fluoropyrimidine-based therapy, though first-line use is under active investigation. <strong>If your tumour is BRAF V600E-mutated, your first-line treatment should be planned with the second-line BEACON-CRC protocol explicitly in the sequence.</strong> The sequencing decision matters; start that conversation at diagnosis, not at progression.</p> </div>

<p class="sources">Sources: BEACON-CRC Trial — Kopetz et al. NEJM 2019 · BEACON-CRC2 — Tabernero et al. · NCCN Colon Cancer v1.2025</p> </section>

<section id="her2"> <h2>HER2 and NTRK — the rare but actionable targets</h2> <hr class="rule">

<h3>HER2 amplification — 3–5% of cases</h3>

<p class="body-text"> HER2 amplification occurs in approximately 3–5% of metastatic colon cancer patients, disproportionately in left-sided, RAS wild-type, BRAF wild-type tumours. It was long under-recognised because HER2 testing was not routine in colorectal cancer. NCCN 2025 now recommends HER2 testing for all Stage IV patients. </p>

<div class="drug-card her"> <span class="drug-badge">Trastuzumab + Pertuzumab / Trastuzumab + Lapatinib</span> <h3>HER2-targeted therapy for HER2-amplified mCRC</h3> <div class="drug-meta"> <div class="dm"><strong>Mechanism:</strong> Dual HER2 blockade prevents receptor dimerisation and downstream signalling</div> <div class="dm"><strong>Evidence:</strong> DESTINY-CRC01 (T-DXd), MOUNTAINEER trial (trastuzumab+tucatinib)</div> <div class="dm"><strong>India cost:</strong> $1,200–$2,000 per cycle (trastuzumab)</div> </div>

<p class="body-text"> In HER2-amplified RAS wild-type metastatic CRC, standard anti-EGFR therapy (cetuximab) is less effective because HER2 amplification provides an alternative growth pathway. HER2-directed combinations — trastuzumab with pertuzumab, lapatinib, or the newer agent tucatinib — have shown meaningful activity in this subset. The MOUNTAINEER trial showed trastuzumab plus tucatinib produced overall response rates of 38% with durable responses in HER2-amplified RAS wild-type mCRC after prior therapy. </p> </div>

<h3>NTRK fusion — less than 1% of cases</h3>

<p class="body-text"> NTRK (Neurotrophic Tropomyosin Receptor Kinase) fusions occur in under 1% of colorectal cancers. They are more common in MSI-H tumours. NTRK-positive tumours respond dramatically to larotrectinib and entrectinib — both of which received tumour-agnostic FDA approval. The response rate in NTRK-positive solid tumours across multiple cancer types is approximately 75%, with durable remissions. In India, larotrectinib costs $3,500–$5,000 per month versus $28,000–$35,000 in the US. </p>

<p class="body-text"> NTRK fusion testing requires either next-generation sequencing (NGS) or FISH — standard IHC does not reliably detect fusions. If your NGS panel has not been run, this is worth requesting, particularly if your tumour has unusual histology or is MSI-H. </p>

<p class="sources">Sources: MOUNTAINEER Trial — Strickler et al. · DESTINY-CRC01 · NCCN Colon Cancer v1.2025 · FDA NTRK Tumour-Agnostic Approval</p> </section>

<section id="side-effects"> <h2>Side effects: what actually differs between the drugs</h2> <hr class="rule">

<p class="body-text"> Each targeted agent has a characteristic toxicity profile. Understanding the differences helps patients prepare and helps oncologists choose between agents when both are clinically appropriate. </p>

<table class="big-table" aria-label="Side effect comparison bevacizumab vs cetuximab"> <thead> <tr> <th style="width:26%">Side effect</th> <th style="width:24%">Bevacizumab</th> <th style="width:25%">Cetuximab / Panitumumab</th> <th style="width:25%">Encorafenib + Cetuximab</th> </tr> </thead> <tbody> <tr> <td class="key">Skin rash (acneiform)</td> <td>Rare</td> <td>Very common — 75–90%. Usually Grade 1–2. Paradoxically: worse rash correlates with better tumour response.</td> <td>Common — similar to cetuximab monotherapy</td> </tr> <tr> <td class="key">Hypertension</td> <td>Common — 25–35%. Requires monitoring and anti-hypertensive medication in significant proportion.</td> <td>Uncommon</td> <td>Uncommon</td> </tr> <tr> <td class="key">Wound healing impairment</td> <td>Significant — must stop bevacizumab at least 4–6 weeks before elective surgery. Critical for patients heading to surgical resection.</td> <td>Minimal</td> <td>Minimal</td> </tr> <tr> <td class="key">Hypomagnesaemia</td> <td>Uncommon</td> <td>Common — EGFR blockade in the kidney causes magnesium wasting. Requires monitoring and supplementation in most patients on long-term cetuximab.</td> <td>Common — same as cetuximab</td> </tr> <tr> <td class="key">Thromboembolic events</td> <td>Increased risk — both arterial (stroke, MI) and venous. Requires careful monitoring, especially in older patients or those with cardiovascular history.</td> <td>Minimal additional risk</td> <td>Minimal additional risk</td> </tr> <tr> <td class="key">Bowel perforation</td> <td>Rare but serious — approximately 1–2%. Risk higher in patients with prior abdominal radiation or bowel obstruction history.</td> <td>Not associated</td> <td>Not associated</td> </tr> <tr> <td class="key">Infusion reactions</td> <td>Rare</td> <td>3–5% with cetuximab. Premedication with antihistamine required. Panitumumab has lower rate (<1%).</td> <td>Low with encorafenib (oral); cetuximab component same as monotherapy</td> </tr> </tbody> </table>

<div class="callout-amber"> <div class="callout-amber-lbl">The bevacizumab-surgery timing issue — critical for international patients</div> <p>Bevacizumab impairs wound healing. If you are receiving bevacizumab and surgery is planned — whether a primary colectomy, a liver resection, or any other procedure — <strong>bevacizumab must be stopped at least 4–6 weeks before the operation and not restarted until wound healing is confirmed, typically 4 weeks post-surgery.</strong> For international patients managing treatment across borders, this timing must be explicitly communicated between your Indian oncologist and your home-country surgeon. Missed communication on this specific point has caused serious complications in patients who continued bevacizumab too close to an elective procedure.</p> </div>

<p class="sources">Sources: NCCN Bevacizumab Safety Guidelines · ESMO mCRC Management Guidelines 2023 · PMC Bevacizumab wound healing data</p> </section>

<section id="india"> <h2>Targeted therapy in India — cost, access, and quality</h2> <hr class="rule">

<div class="qa"> <div class="qa-lbl"><svg width="12" height="12" viewBox="0 0 16 16" fill="none"><path d="M8 1L10.09 5.26L15 6L11.5 9.4L12.18 14.28L8 12.08L3.82 14.28L4.5 9.4L1 6L5.91 5.26L8 1Z" fill="#c97d10"/></svg>Quick answer</div> <div class="qa-q">Are bevacizumab and cetuximab available in India at the same quality as in the US?</div> <p>Yes — both drugs are available at India's accredited private cancer centres, administered according to the same NCCN and ESMO protocols. Bevacizumab biosimilars manufactured by Indian pharma companies under WHO GMP standards are used widely. Cetuximab (imported branded and biosimilar versions) is available at all major oncology centres. Biomarker testing to determine eligibility is performed at CAP-accredited labs. The drugs, protocols, and monitoring are clinically equivalent — the cost is 70–85% lower.</p> </div>

<table class="big-table" aria-label="Targeted therapy cost comparison India vs USA vs UAE"> <thead> <tr> <th>Drug / Combination</th> <th>India (per cycle)</th> <th>USA (per cycle)</th> <th>UAE (per cycle)</th> </tr> </thead> <tbody> <tr> <td class="key">Bevacizumab (5 mg/kg)</td> <td class="hi">$600–$900</td> <td>$4,000–$7,000</td> <td>$2,000–$3,500</td> </tr> <tr> <td class="key">Cetuximab (weekly)</td> <td class="hi">$700–$1,100</td> <td>$5,000–$9,000</td> <td>$2,500–$4,500</td> </tr> <tr> <td class="key">Panitumumab (bi-weekly)</td> <td class="hi">$800–$1,300</td> <td>$6,000–$10,000</td> <td>$3,000–$5,500</td> </tr> <tr> <td class="key">Encorafenib + Cetuximab (BEACON)</td> <td class="hi">$2,800–$4,200</td> <td>$18,000–$28,000</td> <td>$10,000–$16,000</td> </tr> <tr> <td class="key">Trastuzumab (HER2+)</td> <td class="hi">$1,200–$2,000</td> <td>$8,000–$14,000</td> <td>$4,000–$7,000</td> </tr> <tr> <td class="key">Larotrectinib (NTRK+, monthly)</td> <td class="hi">$3,500–$5,000</td> <td>$28,000–$35,000</td> <td>$14,000–$20,000</td> </tr> <tr> <td class="key">Extended RAS/BRAF/HER2 biomarker panel</td> <td class="hi">$180–$320</td> <td>$1,500–$3,500</td> <td>$600–$1,400</td> </tr> </tbody> </table>

<p class="body-text"> The cost difference compounds significantly over a typical treatment course. A patient receiving bevacizumab every 2 weeks for 12 months takes approximately 24–26 cycles. The cost difference between India and the US over that period — $14,000–$23,400 versus $96,000–$182,000 — represents the kind of financial gap that determines whether a family can complete treatment or must stop partway through. </p>

<p class="body-text"> One practical note for the hybrid model — patients who have surgery in India and receive targeted therapy at home. Bevacizumab and cetuximab are available in most countries where GAF Healthcare's patients are based, including Nigeria, Kenya, Bangladesh, and Iraq. The drugs can be procured locally while your Indian oncology team maintains protocol oversight remotely. GAF Healthcare coordinates the treatment plan documentation to make this transition seamless. </p>

<div class="link-box"> <a href="https://gafhealthcare.in/treatments/colon-cancer-treatment">Colon cancer treatment in India — complete guide: targeted therapy, surgery, immunotherapy</a> <p>Full treatment pathway, hospital profiles, cost breakdown, and coordination from first contact to post-treatment surveillance.</p> </div>

<div class="link-box"> <a href="https://gafhealthcare.in/resources/blog/colon-cancer-treatment-india-international-patients">How international patients manage targeted therapy across borders</a> <p>Coordination between Indian and home-country oncologists, drug procurement, monitoring protocols, and surveillance scan scheduling.</p> </div>

<p class="sources">Sources: GAF Healthcare Drug Cost Database 2025 · Apollo, Medanta, Fortis, Max Saket targeted therapy tariffs · WHO GMP Guidelines</p> </section>

<section id="faq"> <h2>Frequently asked questions</h2> <hr class="rule">

<div class="faq-item"> <div class="faq-q">What is the difference between bevacizumab and cetuximab?</div> <div class="faq-a">Bevacizumab blocks VEGF — a protein tumours use to recruit blood vessels — and works regardless of your RAS mutation status. Cetuximab blocks EGFR — a growth receptor on cancer cell surfaces — and only works if your tumour has no RAS mutations. In RAS wild-type, left-sided colon cancer, cetuximab generally produces better responses than bevacizumab. In RAS-mutated disease, only bevacizumab is appropriate. In right-sided tumours, bevacizumab is usually preferred even if RAS is wild-type.</div> </div>

<div class="faq-item"> <div class="faq-q">If I'm RAS wild-type, should I always choose cetuximab over bevacizumab?</div> <div class="faq-a">Not necessarily. Tumour sidedness matters enormously. FIRE-3 and CALGB 80405 both showed that cetuximab's survival advantage over bevacizumab is essentially confined to left-sided primaries (descending colon, sigmoid, rectosigmoid). For right-sided RAS wild-type tumours, the evidence favours bevacizumab. Ask your oncologist specifically: "Given my primary tumour location, which targeted agent has the stronger evidence base for my situation?"</div> </div>

<div class="faq-item"> <div class="faq-q">What is the skin rash from cetuximab and can it be managed?</div> <div class="faq-a">An acneiform rash — red, pimple-like spots on the face, chest, and back — affects 75–90% of patients receiving cetuximab or panitumumab. It typically appears in the first 2–3 weeks of treatment and peaks around week 3–4. Paradoxically, patients who develop a more severe rash tend to have better tumour responses to the drug. Management includes topical antibiotics (doxycycline gel), oral tetracycline antibiotics for grades 2–3, and emollient moisturisers. Severe grade 3 rash — widespread, infected, or affecting quality of life significantly — requires dose modification or treatment interruption. Your oncology team should proactively discuss skin management before the first cycle, not after the rash has appeared.</div> </div>

<div class="faq-item"> <div class="faq-q">Can I receive targeted therapy in India and then continue it at home?</div> <div class="faq-a">Yes — this is a common and workable model. Your Indian oncology team provides a detailed treatment plan specifying the drug, dose, schedule, and monitoring requirements. Your home-country oncologist administers the cycles locally. GAF Healthcare coordinates the transition and remains available for protocol queries throughout treatment. Note: if you are on bevacizumab and surgery is planned at any point, the 4–6 week pre-operative bevacizumab break must be explicitly communicated to both teams.</div> </div>

<div class="faq-item"> <div class="faq-q">My KRAS came back wild-type — am I definitely eligible for cetuximab?</div> <div class="faq-a">Not until you have extended RAS testing. "KRAS wild-type" from a test that only examined KRAS exon 2 is incomplete. Extended RAS testing adds KRAS exons 3 and 4, and NRAS exons 2, 3, and 4. If any of these are mutated, cetuximab is contraindicated and may be harmful. NCCN and ESMO guidelines both specify extended all-RAS testing as mandatory before anti-EGFR therapy. Request the extended panel report specifically and confirm it includes all six exon tests before any cetuximab is given.</div> </div>

<div class="faq-item"> <div class="faq-q">Why does BRAF V600E need encorafenib plus cetuximab rather than just cetuximab?</div> <div class="faq-a">Because of a feedback loop specific to colorectal cancer biology. When you block the mutant BRAF V600E protein with a BRAF inhibitor alone, the cancer cell compensates by upregulating EGFR signalling as an escape route. This makes BRAF inhibitor monotherapy largely ineffective in colorectal cancer — unlike in melanoma, where it works well. Adding cetuximab blocks the EGFR escape route, allowing the BRAF inhibitor to maintain its effect. This dual blockade strategy, validated by the BEACON-CRC trial, is the only approved targeted approach for BRAF V600E metastatic colon cancer in second-line therapy.</div> </div>

<p class="sources">Sources: NCCN Colon Cancer v1.2025 · ESMO mCRC Guidelines 2023 · FIRE-3 BJC 2021 · BEACON-CRC NEJM 2019 · PARADIGM Trial JAMA 2023</p> </section>

<div class="final-cta" role="complementary" aria-label="GAF Healthcare contact"> <h2>The right targeted therapy depends on a test most patients haven't had yet.</h2> <p>Extended RAS, BRAF, HER2, and MSI testing costs $180–$320 in India and takes 7–14 days. Without these results, no targeted therapy decision can be made correctly. GAF Healthcare arranges the complete biomarker panel, interprets results, and builds your personalised treatment plan — at no charge for the assessment.</p> <div class="btns"> <a href="https://gafhealthcare.in/treatments/colon-cancer-treatment" class="btn-w">Get Free Biomarker Review →</a> <a href="https://gafhealthcare.in/resources/blog/colon-cancer-treatment-india-international-patients" class="btn-gh">Full Treatment Guide →</a> </div> </div>

</div> </body> </html>